Late-breaking data shows abbott's amplatzer™ amulet™ occluder offers superior left atrial appendage closure compared to watchman‡ device for people with atrial fibrillation at risk of stroke

Abbott park, ill., aug. 30, 2021 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data from the amulet™ laa occluder ide trial, a multi-center, head-to-head study comparing the company's amplatzer™ amulet left atrial appendage (laa) occluder with the watchman‡ device (boston scientific) to treat patients with atrial fibrillation (afib) at an increased risk of stroke.
ABT Ratings Summary
ABT Quant Ranking